Skip to main content

ZADAXIN (thymalfasin) is well tolerated. During clinical experience involving over 2000 individuals with various diseases distributed over all age groups, no clinically significant adverse reactions attributable to thymosin alpha 1 administration were reported (see table below).

  Disease Adverse Event Rate
Viral Infection Chronic hepatitis B Chronic hepatitis C Human immunodeficiency < 1% drug related adverse events for all indications
Cancer Non-small cell lung cancer Melanoma  
Vaccine adjuvant Hepatitis B vaccine Influenza vaccine
Immune disorders Autoimmune liver disease Primary immune deficiency

Adverse experiences have been infrequent and mild, consisting primarily of local discomfort at the injection site, and rare instances of erythema, transient muscle atrophy, polyarthralgia combined with hand edema, and rash.